NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+3.11%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$427M
AUM Growth
+$427M
(+4.9%)
Cap. Flow
+$16.3M
Cap. Flow
% of AUM
3.81%
Top 10 Holdings %
Top 10 Hldgs %
53.84%
Holding
57
New
18
Increased
15
Reduced
8
Closed
12
Top Buys
| 1 |
Exelixis
EXEL
|
$30.6M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
$19.3M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$16.5M |
| 4 |
Esperion Therapeutics
ESPR
|
$11.3M |
| 5 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$9.23M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$21.7M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$21M |
| 3 |
SHPG
Shire pic
SHPG
|
$20.8M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$17.3M |
| 5 |
Heron Therapeutics
HRTX
|
$11.3M |
Sector Composition
| 1 | Healthcare | 91.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $37M | 5.73% | 222,113 -26,507 | -11% | -$4.42M |
|
|
IMMU
2
DELISTED
Immunomedics Inc
IMMU
| $31.5M | 4.87% | 1,329,104 +247,694 | +23% | +$5.86M |
|
|
3
Exelixis
EXEL
$10.1B
| $30.6M | 4.74% | +1,421,600 | New | +$30.6M |
|
|
DOVA
4
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $24.5M | 3.8% | 820,348 +252,105 | +44% | +$7.54M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $19.3M | 2.98% | +433,500 | New | +$19.3M |
|
6
AstraZeneca
AZN
$248B
| $18.3M | 2.83% | 520,279 +36,279 | +7% | +$1.27M |
|
|
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $18.3M | 2.83% | 404,092 +88,945 | +28% | +$4.02M |
|
8
Pacira BioSciences
PCRX
$1.2B
| $18.2M | 2.81% | 566,508 +87,888 | +18% | +$2.82M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $16.5M | 2.55% | +132,623 | New | +$16.5M |
|
10
Viatris
VTRS
$12.3B
| $15.6M | 2.42% | 432,009 +171,009 | +66% | +$6.18M |
|
|
CLLS
11
Cellectis
CLLS
$258M
| $15.5M | 2.4% | 548,212 +215,458 | +65% | +$6.1M |
|
12
Insmed
INSM
$28.8B
| $15.3M | 2.37% | 646,863 -271,660 | -30% | -$6.42M |
|
13
Sangamo Therapeutics
SGMO
$157M
| $15.2M | 2.35% | 1,066,914 +280,538 | +36% | +$3.98M |
|
|
SAGE
14
DELISTED
Sage Therapeutics
SAGE
| $12.4M | 1.92% | 79,080 +853 | +1% | +$134K |
|
|
15
Esperion Therapeutics
ESPR
$448M
| $11.3M | 1.74% | +287,300 | New | +$11.3M |
|
|
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
| $11.1M | 1.72% | 828,655 -24,031 | -3% | -$323K |
|
17
Abeona Therapeutics
ABEO
$350M
| $10M | 1.55% | 626,804 +257,304 | +70% | +$4.12M |
|
|
BOLD
18
DELISTED
Audentes Therapeutics, Inc
BOLD
| $9.23M | 1.43% | +241,500 | New | +$9.23M |
|
19
Gyre Therapeutics
GYRE
$703M
| $9.18M | 1.42% | 786,865 +248,241 | +46% | +$2.9M |
|
|
STML
20
DELISTED
Stemline Therapeutics, Inc.
STML
| $8.98M | 1.39% | 559,517 +35,893 | +7% | +$576K |
|
21
FibroGen
FGEN
$47.8M
| $8.49M | 1.31% | 135,583 -15,305 | -10% | -$958K |
|
|
TVRD
22
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $8.35M | 1.29% | 435,800 +84,750 | +24% | +$1.62M |
|
|
ECYT
23
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $8.23M | 1.27% | +596,000 | New | +$8.23M |
|
24
Kura Oncology
KURA
$686M
| $6.94M | 1.07% | 381,459 +29,504 | +8% | +$537K |
|
|
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.78M | 1.05% | 102,187 -260,787 | -72% | -$17.3M |
|